RevMed Locks in Acclaimed MRI Pioneer on Eve of National Product Debut

CHARLESTON, SC--(Marketwire - November 17, 2009) - Revolutions Medical Corporation (“RevMed” or the “Company”) (OTCBB: RMCP), producers of the RevVac safety syringe, RevColor, RevDisplay and Rev3D MRI Technology, today announced that president and MRI industry pioneer Tom O’Brien has signed a 3-year employment commitment to the Company, giving RevMed leadership continuity and assured access to his unrivaled distribution relationships.

Mr. O’Brien has more than 25 years of general management experience in the medical device industry. He has held executive positions with medical industry leaders such as Pfizer, Toshiba, and Johnson & Johnson-owned Technicare Corporation. While with Technicare he part of the team responsible for launching MRI technology to teaching hospitals worldwide and has remained an active voice in the medical imaging space.

“Securing Tom’s extended commitment is a victory for RevMed, and an absolutely essential investment toward successfully launching and eventually making universal our MRI software suite,” stated RevMed CEO Ron Wheet. “Few individuals have been as influential in the industry’s development as has Tom, and his ongoing work with RevMed will expose us to distribution channels for our core product lines wholly unavailable to the typical development stage company. As investing in the syringe redesign was vital to the evolution of our RevVac safety syringe, so is this commitment critical to our RevMed, RevDisplay and Rev3D MRI technologies.”

RevMed President Tom O’Brien concluded, “In my 25 years in the space I have never been more excited about a technology’s potential. With our products radiologists will be able to see detail they never thought possible, and potentially extend the reach of MRI into such areas as Alzheimer’s, stroke and breast disease. I am proud to continue to be a part of this ground-breaking launch, and I look forward to unveiling the software at the Radiological Society of North America (RSNA) annual meeting in Chicago November 29 - December 4.”

RevMed will preview RevMed, RevDisplay and Rev3D at the South Building of McCormick Place in Hall A, at booth #6604.

To be added to the RevMed investor email list, please email justin.davis@cirrusfc.com with RMCP in the subject line.

About Revolutions Medical Corporation (www.revolutionsmedical.com)

RevMed’s products include the RevVac safety syringe (FDA Approved), safety blood drawing device and safety IV catheter. RevMed also provides RevColor, RevDisplay and Rev3D -- software solutions and proprietary tools that are compatible with standard MRIs and standard PACS. The software suite’s functionality includes sorting of images, color, 3D and automatic segmentation of images.

Investor Resource Center

Fact Sheet: http://content.stockpr.com/rmcp/files/RMCP_-_Fact_Sheet_09-09-09.pdf

CEO Ron Wheet Audio Interview: http://ir.stockpr.com/revolutionsmedical/media-center/view/33/

RevVac Demo Video: http://www.revolutionsmedical.com/videos/revac_directions_final.wmv

FORWARD-LOOKING STATEMENTS

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.